CD19 CAR T cell therapy for B cell lymphoma or lymphocytic leukemia is the most widely studied clinical indication and is a successful FDA-approved CAR cell therapy9, 51. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.